Sign in
Not yet taking people in Hong KongPhase 4

Romosozumab versus denosumab for bone loss from long-term glucocorticoid use, at 6 years

Compares romosozumab and denosumab on bone density in adults taking long-term glucocorticoids.

Key facts

Who runs it
Tuen Mun Hospital
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years
Status
Not yet recruiting
Phase
Phase 4
People taking part
54 people, planned
Started
1 Sept 2026
Expected to end
1 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Romosozumab
  • Denosumab
Record updated
12 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people already in an earlier trial of romosozumab versus denosumab for bone loss caused by long-term glucocorticoids. They must have stayed on denosumab after month 48 and be willing to have a repeat bone scan (DXA) at 6 years.

Age
18 years and older
Sex
All sexes can join
Disease stage
Bone loss or osteoporosis caused by long-term glucocorticoids (steroid medicines)
Earlier treatment
Must have continued 6-monthly denosumab injections under the skin after month 48, in either the romosozumab or the denosumab group of the earlier trial

Main reasons for not taking part

  • Refuses to stay on denosumab after month 48
  • Takes other osteoporosis drugs after month 48
  • Prednisolone is planned to be reduced or stopped after month 48

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • patients who are continued on 6-monthly subcutaneous injection of DEN in either the ROMO or DEN arms after month 48; (2) those who are willing to have a repeat DXA assessment at the end of 6 years

Who cannot take part

  • patients who are maintained on other anti-osteoporotic drugs after month 48
  • patients who refuse to be maintained on denosumab after month 48
  • patients in whom prednisolone is planned to be tapered or discontinued after month 48

Where in Hong Kong

  • Tuen Mun HospitalHong Kong, Hong KongContact: Chi Chiu Mok, MD, FRCPNot yet recruiting

About the trial

What the trial wants to find out

This is an extended observation study of a RCT comparing the efficacy of romorozumab and denosumab in high-risk patients using long-term glucocorticoids. In the romosozumab arm, patients were shifted to denosumab after the first year. The denosumab arm of patients were continued on denosumab. This study aims to look at the bone mineral density changes in both groups of patients after 6 years.

The 2 groups in the trial

  • romosozumabExisting treatment, for comparison

    romosozumab for 12 months, followed by denosumab

    Treatment: Romosozumab and Denosumab

  • denosumab aloneExisting treatment, for comparison

    Treatment: Denosumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Randomized Controlled Trial At 6 Years
Plain-language title
Romosozumab versus denosumab for bone loss from long-term glucocorticoid use, at 6 yearsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 August 2026